Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 261

Results For "IND"

6326 News Found

Strides receives USFDA approval for Sucralfate oral suspension, 1gm/10 mL
Drug Approval | May 29, 2024

Strides receives USFDA approval for Sucralfate oral suspension, 1gm/10 mL

Strides’ approval for this product marks the 1st Indian approval from the USFDA for this complex formulation


IGC Pharma announces patient enrollment at Neurostudies in Phase 2 trial investigating IGC-AD1
News | May 29, 2024

IGC Pharma announces patient enrollment at Neurostudies in Phase 2 trial investigating IGC-AD1

Advancing IGC-AD1 Toward Commercialization as a Treatment for Agitation in Alzheimer's


Asahi Kasei to acquire Calliditas Therapeutics AB to accelerate growth
News | May 29, 2024

Asahi Kasei to acquire Calliditas Therapeutics AB to accelerate growth

Asahi Kasei will offer to acquire all of the ordinary shares of Calliditas


Roche and Hitachi High-Tech extend partnership for further breakthroughs in diagnostic testing
Clinical Trials | May 28, 2024

Roche and Hitachi High-Tech extend partnership for further breakthroughs in diagnostic testing

The new 10-year contract will focus on strengthening the partnership for continued transformative innovation for patients


AstraZeneca furthers ambition to transform outcomes in early lung cancer at ASCO 2024
News | May 27, 2024

AstraZeneca furthers ambition to transform outcomes in early lung cancer at ASCO 2024

Back-to-back plenary presentations for LAURA and ADRIATIC Phase III trials reinforce the potential of Tagrisso and Imfinzi in early lung cancer settings


Alvotech and Dr. Reddy’s collaborate for commercialization of AVT03 (denosumab)
News | May 27, 2024

Alvotech and Dr. Reddy’s collaborate for commercialization of AVT03 (denosumab)

Dr. Reddy’s gets exclusive commercialization rights in the United States (U.S.) as well as semi-exclusive rights in Europe and United Kingdom (UK)


Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction
Clinical Trials | May 27, 2024

Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction

Through its rare kidney disease portfolio, Novartis is committed to exploring a range of treatment options with different modes of action to slow IgAN progression


Zydus announces completion of Enrolment for Phase II clinical trial of Usnoflast
Clinical Trials | May 25, 2024

Zydus announces completion of Enrolment for Phase II clinical trial of Usnoflast

ALS is a rare, progressive and fatal neurodegenerative disease, with an average life expectancy of 3 to 5 years from the time of symptom onset


Zydus receives final approval from USFDA for Theophylline ER Tablets
Drug Approval | May 25, 2024

Zydus receives final approval from USFDA for Theophylline ER Tablets

Theophylline is used to treat asthma and chronic obstructive pulmonary disease


BaseLaunch announces a new partnership with AbbVie
News | May 24, 2024

BaseLaunch announces a new partnership with AbbVie

Further strengthens BaseLaunch's global pharma industry partnerships